Search - tctmd.com

Displaying 861 - 873 of 873

Sort: Relevancy | Date

Presentation

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

Presenter: R. Khatib

October 26, 2015

News Industry News

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

September 08, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

News Daily News

ITALIC Published: No Benefit to Long-Term DAPT After Stenting

Yael L. Maxwell

March 10, 2015

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

News Daily News

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

August 30, 2013

News Daily News

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Jason Kahn

December 05, 2012

News Daily News

Meta-analysis Questions Benefit of Longer Dual Antiplatelet Therapy Post-PCI

November 28, 2012

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

News Daily News

JUPITER: Rosuvastatin Cuts Heart Risk, Even In LDL-Normal Patients

November 11, 2008

CME

Advertisement

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

ITALIC Published: No Benefit to Long-Term DAPT After Stenting

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Meta-analysis Questions Benefit of Longer Dual Antiplatelet Therapy Post-PCI

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

JUPITER: Rosuvastatin Cuts Heart Risk, Even In LDL-Normal Patients

Aspirin for the Interventionalist: More Than Meets the Eye

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content